- Home
- GAUZ vs MGNX Comparison
GAUZ vs MGNX Comparison
Compare GAUZ & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAUZ
- MGNX
- Stock Information
- Founded
- GAUZ 2009
- MGNX 2000
- Country
- GAUZ Israel
- MGNX United States
- Employees
- GAUZ N/A
- MGNX N/A
- Industry
- GAUZ Industrial Machinery/Components
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- GAUZ Miscellaneous
- MGNX Health Care
- Exchange
- GAUZ Nasdaq
- MGNX Nasdaq
- Market Cap
- GAUZ 156.3M
- MGNX 125.2M
- IPO Year
- GAUZ 2024
- MGNX 2013
- Fundamental
- Price
- GAUZ $8.25
- MGNX $1.26
- Analyst Decision
- GAUZ Strong Buy
- MGNX Hold
- Analyst Count
- GAUZ 4
- MGNX 10
- Target Price
- GAUZ $16.25
- MGNX $6.83
- AVG Volume (30 Days)
- GAUZ 49.9K
- MGNX 647.7K
- Earning Date
- GAUZ 03-11-2025
- MGNX 03-20-2025
- Dividend Yield
- GAUZ N/A
- MGNX N/A
- EPS Growth
- GAUZ N/A
- MGNX N/A
- EPS
- GAUZ N/A
- MGNX N/A
- Revenue
- GAUZ $103,527,000.00
- MGNX $149,962,000.00
- Revenue This Year
- GAUZ $34.05
- MGNX N/A
- Revenue Next Year
- GAUZ $45.89
- MGNX $42.52
- P/E Ratio
- GAUZ N/A
- MGNX N/A
- Revenue Growth
- GAUZ 32.76
- MGNX 155.26
- 52 Week Low
- GAUZ $6.78
- MGNX $1.26
- 52 Week High
- GAUZ $17.10
- MGNX $19.54
- Technical
- Relative Strength Index (RSI)
- GAUZ N/A
- MGNX 19.12
- Support Level
- GAUZ N/A
- MGNX $1.89
- Resistance Level
- GAUZ N/A
- MGNX $2.24
- Average True Range (ATR)
- GAUZ 0.00
- MGNX 0.17
- MACD
- GAUZ 0.00
- MGNX -0.07
- Stochastic Oscillator
- GAUZ 0.00
- MGNX 0.00
About GAUZ Gauzy Ltd. Ordinary Shares
Gauzy Ltd. is a fully-integrated light and vision control company. The group is focused on the research, development, manufacturing, and marketing of smart glass technologies and advanced driver assistance systems (ADAS) to support safe, sustainable, comfortable, and agile user experiences across various industries. The company operates in Germany, France, the United States, Canada, China, Singapore, and the United Arab Emirates. Gauzy partners with brands in aeronautics, automotive, and architecture across more than 30 countries, providing direct fulfilment and leveraging a certified, trained distribution and partner network.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).